Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Christian Rausch, Maja Rothenberg‐Thurley, Annika Dufour, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1234-1244
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Menglin Li, Yimeng Li, Qingyuan Qu, et al.
Cancer Letters (2025), pp. 217460-217460
Closed Access | Times Cited: 2
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Álex Bataller, Alexandre Bazinet, Courtney D. DiNardo, et al.
Blood Advances (2023) Vol. 8, Iss. 4, pp. 927-935
Open Access | Times Cited: 29
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Michael Wysota, Marina Konopleva, Shane Mitchell
Current Oncology Reports (2024) Vol. 26, Iss. 4, pp. 409-420
Open Access | Times Cited: 12
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
Madlen Jentzsch, Lara Bischof, Jule Ussmann, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 31
Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3512-3512
Open Access | Times Cited: 16
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
Andrew A. Lane, Jacqueline S. Garcia, Evangeline G. Raulston, et al.
Blood Advances (2023) Vol. 8, Iss. 3, pp. 591-602
Open Access | Times Cited: 16
Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling
Mehdi Mirzaie, Elham Gholizadeh, Juho J. Miettinen, et al.
Oncogenesis (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019
Martha S. Linet, Rochelle E. Curtis, Sara J. Schonfeld, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102549-102549
Open Access | Times Cited: 6
BCL-2 inhibition in haematological malignancies: Clinical application and complications
Dominic Fowler-Shorten, Charlotte Hellmich, Matthew Markham, et al.
Blood Reviews (2024) Vol. 65, pp. 101195-101195
Closed Access | Times Cited: 5
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Álex Bataller, Hagop M. Kantarjian, Alexandre Bazinet, et al.
Haematologica (2024)
Open Access | Times Cited: 5
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group
Carlos Jiménez‐Vicente, Paola Charry, Sandra Castaño‐Díez, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 256-267
Closed Access | Times Cited: 5
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
Joseph G.W. McCarter, David Nemirovsky, Christopher Famulare, et al.
Blood Advances (2023) Vol. 7, Iss. 17, pp. 5000-5013
Open Access | Times Cited: 13
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
Ga‐Young Song, Hyeon-Jong Kim, Tae‐Hyung Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Integrated Genomics Reveal Potential Resistance Mechanisms of PANoptosis‐Associated Genes in Acute Myeloid Leukemia
Cong Liang, Zhi‐Qing Long, Mengjie Lei, et al.
Molecular Carcinogenesis (2025)
Closed Access
Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives
Zahra Khosroabadi, Samaneh Azaryar, Hassan Dianat‐Moghadam, et al.
Molecular Medicine (2025) Vol. 31, Iss. 1
Open Access
Maintenance Therapy in AML: What Is the Future Potential?
Hannah Goulart, Andrew H. Wei, Tapan M. Kadia
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 38-49
Open Access
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
Jordi Esteve, Arnon Nagler, Myriam Labopin, et al.
American Journal of Hematology (2025)
Closed Access
Lymphoma and leukemia occurring during pregnancy
Adam Zayac, Ogechukwu Egini, Neil Palmisiano, et al.
Seminars in Perinatology (2025) Vol. 49, Iss. 2, pp. 152041-152041
Open Access
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Carlos Jiménez‐Vicente, Jordi Esteve, Mónica Baile-González, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
The role of the primitive marker CD133 in CD34‐negative acute myeloid leukemia for the detection of leukemia stem cells
Tom Reuvekamp, Luca L. G. Janssen, Lok Lam Ngai, et al.
Cytometry Part B Clinical Cytometry (2024)
Open Access | Times Cited: 2
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
Klaus Geißler, Zdeněk Kořı́stek, Teresa Bernal, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 5, pp. 1734-1745
Open Access | Times Cited: 2
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
Michael J. Hochman, Megan Othus, Robert P. Hasserjian, et al.
Leukemia (2023) Vol. 37, Iss. 9, pp. 1915-1918
Open Access | Times Cited: 6
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Christoph Röllig
Hematology (2023) Vol. 2023, Iss. 1, pp. 175-185
Closed Access | Times Cited: 5
Assessment of 2022 European LeukemiaNet risk classification system in real‐world cohort from China
Enbo Chen, Changqing Jiao, Jian Yu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 24, pp. 21615-21626
Open Access | Times Cited: 5
Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
Mihee Kim, Seo-Yeon Ahn, Tae‐Hyung Kim, et al.
Hematology (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top